Next Article in Journal
Unravelling Metagenomics Approach for Microbial Biofuel Production
Next Article in Special Issue
Role of Fiber Shaft Length in Tumor Targeting with Ad5/3 Vectors
Previous Article in Journal
Design, Optimization and Validation of the ARMS PCR Protocol for the Rapid Diagnosis of Wilson’s Disease Using a Panel of 14 Common Mutations for the European Population
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 13
Issue 11
10.3390/genes13111941
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

by
Tasneem Farhad
†,
Keila Neves
†,
Patrick Arbuthnot
and
Mohube Betty Maepa
*
Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Genes 2022, 13(11), 1941; https://doi.org/10.3390/genes13111941
Submission received: 28 September 2022 / Revised: 19 October 2022 / Accepted: 20 October 2022 / Published: 25 October 2022
(This article belongs to the Special Issue From Enemies to Friends: Converting Disease-Causing Viruses to Therapeutic Tools)
Browse Figure
Review Reports Versions Notes

Abstract

Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest in developing these vectors as vaccines and therapies against other viruses of health importance such as hepatitis B virus (HBV). Current hepatitis B therapies are not curative; hence, chronic hepatitis B remains the major risk factor for development of liver disease and death in HBV-infected individuals. The ability to induce a robust immune response and high liver transduction efficiency makes adenoviral vectors attractive tools for anti-HBV vaccine and therapy development, respectively. This review describes recent developments in designing adenoviral-vector-based therapeutics and vaccines against HBV infection.
Keywords: adenovirus; gene therapy; hepatitis B virus; vaccine; viral vectors adenovirus; gene therapy; hepatitis B virus; vaccine; viral vectors

Share and Cite

MDPI and ACS Style

Farhad, T.; Neves, K.; Arbuthnot, P.; Maepa, M.B. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes 2022, 13, 1941. https://doi.org/10.3390/genes13111941

AMA Style

Farhad T, Neves K, Arbuthnot P, Maepa MB. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes. 2022; 13(11):1941. https://doi.org/10.3390/genes13111941

Chicago/Turabian Style

Farhad, Tasneem, Keila Neves, Patrick Arbuthnot, and Mohube Betty Maepa. 2022. "Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics" Genes 13, no. 11: 1941. https://doi.org/10.3390/genes13111941

APA Style

Farhad, T., Neves, K., Arbuthnot, P., & Maepa, M. B. (2022). Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes, 13(11), 1941. https://doi.org/10.3390/genes13111941

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop